肝硬化并发急性肾损伤临床管理现状与挑战

doi:10.3969/j.issn.1672-5069.2022.06.002

摘要/Abstract

Key words: Liver cirrhosis, Acute kidney injury, Acute kidney diseases, Hepatorenal syndrome

蒋莹莹, 丁惠国. 肝硬化并发急性肾损伤临床管理现状与挑战[J]. 实用肝脏病杂志, 2022, 25(6): 764-767.

Jiang Yingying, Ding Huiguo. Current status and challenges of clinical management of cirrhotics with acute kidney injury[J]. Journal of Practical Hepatology, 2022, 25(6): 764-767.

[1] Tonon M, Rosi S, Gambino CG, et al. Natural history of acute kidney disease in patients with cirrhosis. J Hepatol, 2021, 74(3):578-583.
[2] Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol, 2015, 62(4):968-974.
[3] Kellum John A, Lameire N, Aspelin P, et al. Kidneydisease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. 2012.
[4] Thapa P, Kc S, Hamal AB, et al. Prevalence ofacute kidney injury in patients with liver cirrhosis. J Nepal Med Assoc, 2020, 58(228):554-559.
[5] Duah A, Duah F, Ampofo-Boobi D, et al. Acutekidney injury in patients with liver cirrhosis: Prevalence, Ppredictors, and in-hospital mortality at a district hospital in Ghana. Biomed Res Int, 2022, 2022.
[6] Choi YJ, Kim JH, Koo JK, et al. Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal. Clin Mol Hepatol, 2014, 20(2):185-191.
[7] Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep, 2017, 5(2):127-137.
[8] Wong F, O'Leary JG, Reddy KR, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology, 2013, 145(6):1280-1288,e1.
[9] Huelin P, Solà E, Elia C, et al. Neutrophilgelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: A prospective study. Hepatology, 2019, 70(1):319-333.
[10] Tandon P, James MT, Abraldes JG, et al. Relevance ofnew definitions to incidence and prognosis of acute kidney injury in hospitalized patients with cirrhosis: A retrospective population-based cohort study. PloS one, 2016, 11(8):e0160394.
[11] Huelin P, Piano S, Solà E, et al. Validation of astaging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure. Clin Gastroenterol H, 2017, 15(3):438-445,e5.
[12] Allegretti AS, Ortiz G, Wenger J, et al. Prognosis ofacute kidney injury and hepatorenal syndrome in patients with cirrhosis: A prospective cohort study. Int J Nephrol, 2015, 2015.
[13] Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology, 2013, 57(2):753-762.
[14] Fernández J, Piano S, Bartoletti M, et al. Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. J Hepatol, 2021, S101-S117.
[15] Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Digest Liver Dis, 2017, 49(1):3-10.
[16] Patidar K R, Naved M A, Grama A, et al. Acutekidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. J Hepatol, 2022, 77(1):108-115.
[17] Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol, 2019, 71(4):811-822.
[18] Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology, 2010, 51(2):576-584.
[19] Nguyen-Tat M, Jäger J, Rey JW, et al. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United Eur Gastroent, 2019, 7(4):529-537.
[20] Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology, 2019, 157(1):149-162.
[21] Feyssa E, Ortiz J, Grewal K, et al. MELD score less than 15 predicts prolonged survival after transjugular intrahepatic portosystemic shunt for refractory ascites after liver transplantation. Transplantation, 2011, 91(7):786-792.
[22] Sourianarayanane A, Raina R, Garg G, et al. Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients. Int Urol Nephrol, 2014, 46(4):793-800.
[23] EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69(2):406-460.
[24] Jo SK, Yang J, Hwang SM, et al. Role of biomarkers as predictors of acute kidney injury and mortality in decompensated cirrhosis. Sci Rep-UK, 2019, 9(1):14508.
[25] Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology, 2014, 60(2):622-632.
[26] Kim TH, Seo YS, Kang SH, et al. Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study. Liver Int, 2020, 40(12):3083-3092.
[27] Lee HA, Seo YS. Current knowledge about biomarkers of acute kidney injury in liver cirrhosis. Clin Mol Hepatol, 2022, 28(1):31-46.
[28] Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. New Engl J Med, 2014, 371(1):58-66.
[29] Bassegoda O, Huelin P, Ariza X, et al. Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. J Hepatol, 2020, 72(6):1132-1139.
[30] Si J, Yu C, Guo Y, et al. Chronic hepatitis B virus infection and risk of chronic kidney disease: a population-based prospective cohort study of 0.5 million Chinese adults. BMC Med, 2018, 16(1):93.
[31] 段英, 王笑梅, 全敏, et al. 肝硬化患者合并慢性肾脏疾病患病率分析. 中国肝脏病杂志(电子版), 2018, 10(3):43-47.
[32] Männistö VT, Salomaa V, Färkkilä M, et al. Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver Int, 2021, 41(11):2590-2600.
[33] Francoz C. Acute kidney injury in cirrhosis: An immediate threat but also a ticking time bomb. J Hepatol, 2020, 72(6):1043-1045.
[34] Maiwall R, Pasupuleti SSR, Bihari C, et al. Incidence, risk factors, and outcomes of transition of acute kidney injury to chronic kidney disease in cirrhosis: A prospective cohort study. Hepatology, 2020, 71(3):1009-1022.

肝硬化并发急性肾损伤临床管理现状与挑战

Current status and challenges of clinical management of cirrhotics with acute kidney injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韩涛, 刘艳迪, 胡家轩. 肝病合并肾损伤临床诊治新进展[J]. 实用肝脏病杂志, 2022, 25(6): 761-763.
[2]	韩芳, 李佳峥, 南月敏. 肝硬化并发急性肾损伤诊治进展[J]. 实用肝脏病杂志, 2022, 25(6): 768-771.
[3]	沈亦亮, 沈冬元, 陈永莹, 江凯, 朱逸明, 葛尚. 肝硬化患者肝内LR-3类结节恶变风险评估及预测模型的建立^*[J]. 实用肝脏病杂志, 2022, 25(6): 836-839.
[4]	徐超, 李兰, 罗东, 赵海云, 彭飞. TIPS术治疗的肝硬化并发EVB患者医院内死亡风险预测模型的构建与应用^*[J]. 实用肝脏病杂志, 2022, 25(6): 840-843.
[5]	林秀慧, 李南, 张娇珍, 符庆忠, 林秀华. 慢性HBV感染者外周血PNPLA3/PRKAA1基因多态性与肝硬化发生关系研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 844-847.
[6]	朱海艳, 范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志, 2022, 25(6): 848-852.
[7]	孙静, 张伟伟, 马智勇, 代树本, 邓彦东. 经颈静脉肝内门体分流术联合胃冠状静脉栓塞术治疗乙型肝炎肝硬化并发食管胃静脉曲张患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 853-856.
[8]	李响, 张铁英, 张旭辉, 孟繁坤. 基于超声参数的半定量评分评估乙型肝炎肝硬化食管静脉曲张价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(6): 857-860.
[9]	张耀辉, 郑章增, 高星, 张亚利. 超声造影时间-强度曲线诊断肝硬化患者肝内小结节病灶价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 861-864.
[10]	詹致远, 申洋, 王凡冰. 内镜下套扎术联合奥美拉唑和奥曲肽治疗肝硬化并发食管静脉曲张首次出血患者短期疗效分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 865-868.
[11]	沈一芃, 祝峻峰. 肝硬化并发自发性细菌性腹膜炎临床研究进展^*[J]. 实用肝脏病杂志, 2022, 25(6): 909-912.
[12]	南月敏, 李佳峥. 肝硬化与感染[J]. 实用肝脏病杂志, 2022, 25(5): 609-611.
[13]	罗楠, 李荣宽. 肝硬化并发自发性细菌性腹膜炎诊治现状[J]. 实用肝脏病杂志, 2022, 25(5): 616-619.
[14]	龚豪, 黄丽, 张庆红, 李涛, 史秀岩. 应用尿微量白蛋白、β2-微球蛋白和N-乙酰-β-D氨基葡萄糖苷酶评估失代偿期肝硬化患者肾损伤效能研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 681-684.
[15]	李婷, 毛小荣, 张雪梅, 李俊峰. 脾切除术与TIPS术治疗肝硬化患者门静脉血栓发生率比较^*[J]. 实用肝脏病杂志, 2022, 25(5): 685-688.